share_log

Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38

Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38

Evercore ISI集团维持Akero Therapeutics的跑赢大盘,将目标股价下调至38美元
Benzinga ·  05/15 09:17

Evercore ISI Group analyst Liisa Bayko maintains Akero Therapeutics (NASDAQ:AKRO) with a Outperform and lowers the price target from $50 to $38.

Evercore ISI集团分析师丽莎·贝科维持Akero Therapeutics(纳斯达克股票代码:AKRO)的跑赢大盘,并将目标股价从50美元下调至38美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发